January 17, 2018 / 4:55 PM / 4 months ago

BRIEF-Transgene Says ‍First Patient Dosed In China In Trial Of T101​

Jan 17 (Reuters) - TRANSGENE SA:

* ‍FIRST CHRONIC HEPATITIS B PATIENT DOSED IN CHINA IN A PHASE 1 TRIAL OF T101​

* ‍FIRST DATA READOUT FROM STUDY IS EXPECTED AT BEGINNING OF 2019​

* ‍TRIAL WILL INCLUDE UP TO 36 PATIENTS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below